Last update 21 Nov 2024

VAC-18193

Overview

Basic Info

Drug Type
Recombinant vector vaccine, Prophylactic vaccine
Synonyms
Ad26.RSV.preF/RSV preF Protein(Janssen Vaccines & Prevention)
Target-
Mechanism
Immunostimulants
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Respiratory Syncytial Virus InfectionsPhase 3
CA
21 Jul 2021
Respiratory Syncytial Virus InfectionsPhase 3
US
21 Jul 2021
Respiratory Syncytial Virus InfectionsPhase 3
ZA
21 Jul 2021
Respiratory Syncytial Virus InfectionsPhase 3
BR
21 Jul 2021
Respiratory Syncytial Virus InfectionsPhase 3
US
21 Jul 2021
Respiratory Syncytial Virus InfectionsPhase 3
BR
21 Jul 2021
Respiratory Syncytial Virus InfectionsPhase 3
CA
21 Jul 2021
Respiratory Syncytial Virus InfectionsPhase 2
CA
21 Jul 2021
Respiratory Syncytial Virus InfectionsPhase 2
ZA
21 Jul 2021
Respiratory Syncytial Virus InfectionsPhase 1
CA
21 Jul 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
25,236
Placebo
lkqnhvixwa(ugkoolhkjw) = zzrlbhnyau iwefiiqrpl (xpyepdyamn, wgxvdllmsg - kmanuzewmw)
-
08 Feb 2024
Phase 3
1,124
RSV preF+Ad26.RSV.preF
(Group 1 (Cohort 1): Ad26.RSV.preF and RSV preF Protein)
twgutozbrf(ddtmysbklr) = vzvqrzwrrd lovfnivoyw (chkpqmfjjs, fvvzdoajqu - wcridmllkq)
-
04 Oct 2023
placebo
(Group 2 (Cohort 1): Placebo)
twgutozbrf(ddtmysbklr) = rzyazlotwz lovfnivoyw (chkpqmfjjs, ckurcfqley - frbbbdrgar)
Phase 3
250
RSV preF Protein+Ad26.RSV.preF
(Group 1 (Phase 3 CTM): Ad26.RSV.preF 1.0*10^11 vp + RSV preF Protein 150 mcg)
uqfvllojxs(ikxvmgueqq) = hhgtfvlixh agujalznel (ldhlupjjud, vpgwfexlod - hjufsvjaxl)
-
11 Sep 2023
RSV preF Protein+Ad26.RSV.preF
(Group 2 (Phase 2b CTM): Ad26.RSV.preF 1.0*10^11 vp + RSV preF Protein 150 mcg)
uqfvllojxs(ikxvmgueqq) = axpikdobis agujalznel (ldhlupjjud, nsdvndyyal - eehxlsqzck)
Phase 1/2
48
adenovirus serotype 26 respiratory syncytial virus e pre-fusion conformation stabilized F-protein (Ad26.RSV.preF)
(Cohort 0 (Adults): Ad26.RSV.preF)
hqonbjthbf(atahhlfaka) = ohauydizbq vwekahntre (fwprzmelxg, kvkulssmfi - syxjfeswnx)
-
23 Jun 2023
(Cohort 0 (Adults): Placebo)
hqonbjthbf(atahhlfaka) = bfnscjasza vwekahntre (fwprzmelxg, rtndwjqlha - fdmswbgvst)
Phase 1/2
38
Nimenrix
(Placebo/Nimenrix)
snfsjkkmxx(mgggyecfeo) = dipisxkqka bnwrzuswxb (vtkusapijr, jyliytmdqq - wbssmvlida)
-
30 Nov 2022
(Ad26.RSV.preF)
snfsjkkmxx(mgggyecfeo) = ceisorjajf bnwrzuswxb (vtkusapijr, aqbbwxhdlf - mqxgsfxmxt)
Phase 2
180
(Group 1: Ad26.RSV.preF (1*10^11 vp) Plus Fluarix Then Placebo)
rcgngmqfqs(nnupwafpmq) = ramujshufw pjiarqmgss (dvgwurqtdx, xtrxdpvyft - gxptmfmsbs)
-
18 Aug 2021
(Group 2: Placebo Plus Fluarix Then Ad26.RSV.preF (1*10^11 vp))
rcgngmqfqs(nnupwafpmq) = ghsmovtxek pjiarqmgss (dvgwurqtdx, yfdzhokhok - neqlbpkuzj)
Phase 2
64
(Ad26.RSV.preF (1*10^11 vp))
nkegzdhlsk(kxgqkiczkm) = ejbwmtlefx aojxbmctrp (rhnapagios, mofggwvvhh - ezabxhgmrm)
-
23 Jul 2021
placebo
(Placebo)
nkegzdhlsk(kxgqkiczkm) = lilegtybez aojxbmctrp (rhnapagios, pkqltqvcul - wurkqlyepv)
Phase 2
180
(control)
(tfukqggqsy) = nfzkqzlhyz qbwsjyghzc (smaqqirhis )
Positive
24 Feb 2021
(coadministration)
(tfukqggqsy) = rwdirtymvt qbwsjyghzc (smaqqirhis )
Phase 1
72
(uqpzlfjlfr) = No serious adverse events were related to vaccination. guxokjidpy (bkeahgsvse )
Positive
17 Aug 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free